Title
Category
Credits
Event date
Cost
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will discuss these novel agents’ indications, risks, and benefits and will address which patient populations are most likely to benefit from particular agents. In addition, early-phase clinical trials and emerging therapies will be explored.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore the most recent advances of this rapidly evolving therapy, including current data on its efficacy, limitations and challenges in the treatment of multiple myeloma and solid tumors. It will provide an overview of currently existing guidelines for CAR T-cell therapy and will describe best practices in determining individuals’ eligibility for this type of therapy, including factors that may affect treatment efficacy and outcomes.
  • Disease management
  • Health equity
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will review the impact of poorer SDOH status on cancer care, disease progression, outcomes, access to treatment and many other aspects. It will also present care models, strategies and resources to help health care professionals best confront the challenges faced by many individuals with cancer.
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This session will examine the genetic approaches being explored for these diseases, such as the introduction of a corrected or modified β-globin gene and gene-sequence editing. It will also explore the genetic modalities utilized, such as genome-editing technologies including the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene-editing system and lentiviral vectors. The safety, efficacy and challenges associated with these therapies will also be outlined.
  • Behavioral health
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will discuss the current approach for screening and management of these complications and will review data regarding the negative associations among psychological distress, health outcomes, successful HSCT, and increased mortality. Barriers in the delivery of psychosocial care and care models to address these issues will also be outlined.
  • Disease management
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will provide participants with insight into newer approaches that effectively integrate standard interventions into management plans tailored to the individual’s particular symptoms, review the value of pulmonary rehabilitation, and outline the effective evaluation of therapeutic responses.
  • Disease management
  • Vision
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
This activity will examine risk factors for glaucoma that will assist health care professionals (HCPs) in the early identification of this condition in general primary eye care practice. Individual risk factors will be discussed, and pertinent literature will be reviewed to provide insight into how certain factors in combination, such as Krukenberg spindles, homogeneous trabecular meshwork pigmentation and iris transillumination defects can indicate an increased risk and alert HCPs to the presence of this disorder. A new tool will be introduced to help recommend when specific glaucoma testing is indicated.
  • Disease management
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
$0.00
This activity will review the symptoms and signs of SM, provide an overview of new and current therapies and identify SM guideline updates. The value of an interdisciplinary team–based approach along the continuum of care for affected individuals will also be discussed as a definitive step toward optimizing outcomes. 
  • Disease management
  • Vision
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
Ocular Anterior Surface Disease or dry eye syndrome affects nearly 16 million Americans and can be a common and chronic problem for adults, especially for those of advanced age, causing symptoms that interfere with eye comfort, function and quality of life. Competent evaluation to determine the etiology of dry eye syndrome is necessary for successful symptom management as therapeutic regimens must be specific to the underlying causes to be effective. This activity will examine the multiple parts of eye anatomy, the dysfunction of which may contribute to dry eye syndrome, including the tear film, ocular anterior surface and Meibomian gland, and identify complications that can result when dry eye is left untreated. Importantly, a thorough review of optimal treatment regimens will be provided, as well as updates on newer and emerging targeted treatments, with a focus on providing relief and preventing further damage to the eye.
  • Disease management
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will provide participants with insight into newer approaches that effectively integrate standard interventions into management plans tailored to the individual’s particular symptoms, review the value of pulmonary rehabilitation, and outline the effective evaluation of therapeutic responses.

Pages